Mechanisms of vanadium action: Insulin-mimetic or insulin-enhancing agent?

Canadian Journal of Physiology and Pharmacology

Volumn 78, Issue 10, 2000, Pages 829-847

  Cam, M C ^a   Brownsey, R W ^a   McNeill, J H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Insulin enhancing; Insulin like; Insulin mimetic; Vanadium

Indexed keywords

VANADIUM;

CARBOHYDRATE METABOLISM; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL;

EID: 0033763296     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y00-053     Document Type: Conference Paper

References (164)

1. The effects of orthovanadate on fatty acid synthesis in isolated rat hepatocytes
2. Vanadyl sulfate does not enhance insulin action in patients with Type I diabetes
3. Treatment of streptozotocin-induced diabetic rats with vanadate and phlorizin prevents the overexpression of the liver insulin receptor gene
4. Vanadate ions: Central nervous system action on glucoregulation
5. The transcription factor CCAAT/enhancer-binding protein beta regulates gluconeogenesis and phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes
6. Phlorizin or vanadate treatment reverses impaired expression of albumin and hepatocyte nuclear factor 1 in diabetic rats
7. Treatment of BB rats with vanadyl sulphate
8. Effect of streptozotocin-induced diabetes on GLUT4 phosphorylation in rat adipocytes
9. Mechanism of inhibition of glycolysis by vanadate
10. Effect of vanadate administration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocin-diabetic rats
11. Insulin-like effects of vanadate and selenate on the expression of glucose-6-phosphate dehydrogenase and fatty acid synthase in diabetic rats
12. PI 3-kinase activation is required for insulin stimulation of glucose transport into L6 myotubes
13. Effect of vanadate on the cellular accumulation of pp15, an apparent product of insulin receptor tyrosine kinase action
14. In vivo insulin resistance in streptozotocin-diabetic rats-evidence for reversal following oral vanadate treatment
15. Impaired insulin action but normal insulin receptor activity in diabetic rat liver: Effect of vanadate
16. Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects
17. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus
18. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
19. Glycogenolytic, noninsulin-like effects of vanadate on rat hepatocyte glycogen synthase and phosphorylase
20. Vanadate inhibits expression of the gene for phosphoenolpyruvate carboxykinase (GTP) in rat hepatoma cells
21. Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats
22. Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats
23. Vanadate treatment markedly increases glucose utilization in muscle of insulin-resistant fa/fa rats without modifying glucose transporter expression
24. Oral vanadate decreases muscle insulin resistance in obese fa/fa rats
25. Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism: Effects on glycolytic and gluconeogenic enzymes, and on glucose transporter GLUT2
26. Phlorizin treatment of diabetic rats partially reverses the abnormal expression of genes involved in hepatic glucose metabolism
27. Tissue-specific correction of lipogenic enzyme gene expression in diabetic rats given vanadate
28. Evidence for selective effects of vanadium on adipose cell metabolism involving actions on cAMP-dependent protein kinase
29. Vanadate inhibits glucose output from isolated perfused rat liver
30. Long-term effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats
31. In vivo antidiabetic actions of naglivan, an organic vanadyl compound in streptozotocin-induced diabetes
32. Concentration-dependent glucose-lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin-diabetic rats
33. Partial preservation of pancreatic beta-cells by vanadium-evidence for long-term amelioration of diabetes
34. Distinct glucose lowering and beta cell protective effects of vanadium and food restriction in streptozotocin-diabetes
35. Effect of sodium vanadate on deoxyribonucleic acid and protein syntheses in cultured rat calvariae
36. Okadaic acid, vanadate, and phenylarsine oxide stimulate 2-deoxyglucose transport in insulin-resistant human skeletal muscle
37. Exercise increases susceptibility of muscle glucose transport to activation by various stimuli
38. Mechanisms of inhibition of lipolysis by insulin, vanadate and peroxovanadate in rat adipocytes
39. Lipid synthesis in isolated rat hepatocytes: Activation by insulin and vanadate and inhibition by ouabain
40. Effects of chronic administration of vanadate to the rat on the sensitivity of glycolysis and glycogen synthesis in skeletal muscle to insulin
41. Selectivity of the insulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle
42. The relationship between the transport of glucose and cations across cell membranes in isolated tissues
43. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus
44. Effect of in vivo vanadate treatment on insulin receptor tyrosine kinase activity in partially pancreatectomized diabetic rats
45. Vanadate stimulation of 2-deoxyglucose transport is not mediated by PI3-kinase in human skeletal muscle
46. Bis(N,N-dimetheylhydroxamido)-hydroxooxovanadate inhibition of protein tyrosine phosphatase activity in intact cells
47. Toxicity studies on one-year treatment of non-diabetic and streptozotocin-diabetic rats with vanadyl sulphate
48. p125fak tyrosine phosphorylation and focal adhesion assembly: Studies with phosphotyrosine phosphatase inhibitors
49. Electron paramagnetic resonance studies and insulin-like effects of vanadium in rat adipocytes
50. Studies on the mass action effect of glucose in NIDDM and IDDM: Evidence for glucose resistance
51. Activation of mitogen activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation
52. +-ATPase inhibitor
53. Insulin-like effects of vanadate in isolated rat adipocytes
54. Vanadium activates or inhibits receptor and non-receptor protein tyrosine kinases in cell-free experiments, depending on its oxidation state. Possible role of endogenous vanadium in controlling cellular protein tyrosine kinase activity
55. Vanadate activates membranous nonreceptor protein tyrosine kinase in rat adipocytes
56. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene
57. Vanadate increases cell surface insulin binding and improves insulin sensitivity in both normal and insulin-resistant rat adipocytes
58. Multifunctional actions of vanadium compounds on insulin signaling pathways-evidence for preferential enhancement of metabolic versus mitogenic effects
59. Vanadate augments insulin binding and prolongs insulin action in rat adipocytes
60. Vanadate augments insulin-stimulated insulin receptor kinase activity and prolongs insulin action in rat adipocytes. Evidence for transduction of amplitude of signaling into duration of response
61. Vanadate normalizes hyperglycemia and phosphoenolpyruvate carboxykinase mRNA levels in ob/ob mice
62. Regulation of lipogenic enzyme expression by glucose in liver and adipose tissue: Is glucose 6-phosphate the signalling metabolite?
63. Improved glucose tolerance by acute vanadate but not by selenate exposure in genetically obese rats (fa/fa)
64. Insulin-like vs. non-insulin-like stimulation of glucose metabolism by vanadium, tungsten, and selenium compounds in rat muscle
65. Insulin-like effects of vanadate on glucokinase activity and fructose 2,6-bisphosphate levels in the liver of diabetic rats
66. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies
67. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus
68. Vanadate raises fructose 2,6-bisphosphate concentrations and activates glycolysis in rat hepatocytes
69. The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insulin-receptor level
70. Simultaneous stimulation of fatty acid synthesis and oxidation in rat hepatocytes by vanadate
71. Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers
72. Effect of acute and chronic vanadate administration on sugar transport in rat jejunum
73. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects
74. Binding of vanadate to human serum transferrin
75. 2 and vanadate stimulate tyrosine phosphorylation of potential target proteins for the insulin receptor kinase in intact cells
76. Skeletal muscle mitogen-activated protein kinases and ribosomal S6 kinases. Suppression in chronic diabetic rats and reversal by vanadium
77. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats
78. Vanadate enhances the stimulatory action of insulin on DNA synthesis in cultured mouse mammary gland
79. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate
80. Insulin-mimetic effects of vanadate in primary cultures of rat hepatocytes
81. Purification and characterization of a 40 S ribosomal protein S6 kinase from vanadate-stimulated Swiss 3T3 cells
82. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression
83. The effect of vanadate on glucose transport and metabolism in rat small intestine
84. In vivo effects of vanadate on hepatic glycogen metabolizing and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals
85. Numerous proteins phosphorylated on tyrosine and enhanced tyrosine kinase activities in vanadate-treated NIH 3T3 fibroblasts
86. Evidence that translocation of the glucose transport activity is the major mechanism of insulin action on glucose transport in fat cells
87. Effects of oral vanadyl treatment on diabetes induced alterations in the heart GLUT4 transporter
88. Effect of vanadate on glucose transporter (Glut4) intrinsic activity in skeletal muscle plasma membrane giant vesicles
89. Vanadate stimulates bone cell proliferation and bone collagen synthesis in vitro
90. Evidence for the distinct vanadyl(+4)-dependent activating system for manifesting insulin-like effects
91. Antilipolytic actions of vanadate and insulin in rat adipocytes mediated by distinctly different mechanisms
92. Peroxovanadate but not vanadate exerts insulin-like effects in human adipocytes
93. Vanadyl(IV) complexes with pyruvate kinase: Activation of the enzyme and electron paramagnetic resonance properties of ternary complexes with the protein
94. L'emploi therapeutique des derives du vanadium
95. Glutathione reduces cytoplasmic vanadate. Mechanism and physiological implications
96. Synergistic interaction of magnesium and vanadate on glucose metabolism in diabetic rats
97. Glucose transporter gene expression: Regulation of transcription and mRNA stability
98. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action
99. Vanadate stimulates in vivo glucose uptake in brain and arrests food intake and body weight gain in rats
100. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus
101. Effects of vanadate on 6-phosphofructo 2-kinase activity and fructose 2,6-bisphosphate levels in cultured rat hepatocytes
102. Oral administration of vanadate to diabetic rats restores liver 6-phosphofructo-2-kinase content and mRNA
103. Vanadate fully stimulates insulin receptor substrate-1 associated phosphatidyl inositol 3-kinase activity in adipocytes from young and old rats
104. Toxicological aspects of vanadyl sulphate on diabetic rats: Effects on vanadium levels and pancreatic B-cell morphology
105. The insulin-like effect of vanadate on lipolysis in rat adipocytes is not accompanied by an insulin-like effect on tyrosine phosphorylation
106. From vanadis to atropos: Vanadium compounds as pharmacological tools in cell death signalling
107. Vanadate stimulates system A amino acid transport activity in skeletal muscle. Evidence for the involvement of intracellular pH as a mediator of vanadate action
108. Mechanism on insulin-like action of vanadyl sulfate: Studies on interaction between rat adipocytes and vanadium compounds
109. Mechanisms of action of vanadium
110. Vanadyl (IV) and vanadate (V) binding to selected endogenous phosphate, carboxyl, and amino ligands; calculations of cellular vanadium species distribution
111. Vanadate affects glucose metabolism of human erythrocytes
112. Regulation of gene expression by insulin
113. Vanadate stimulates D-glucose transport into sarcolemmal vesicles from rat skeletal muscles
114. Vanadium compounds as insulin mimics
115. Vanadate induces the recruitment of GLUT4 glucose transporter to the plasma membrane of rat adipocytes
116. Long-term effects of vanadyl treatment on streptozocin-induced diabetes in rats
117. Chelation of intracellular calcium prevents stimulation of glucose transport by insulin and insulinomimetic agents in the adipocyte. Evidence for a common mechanism
118. Insulinlike effects of vanadate: On hepatic glycogen metabolism in nondiabetic and streptozocin-induced diabetic rats
119. Long-term effects of vanadate treatment on glycogen metabolizing and lipogenic enzymes of liver in genetically diabetic (db/db) mice
120. Effects of high sucrose diet on insulin-like effects of vanadate in diabetic rats
121. Decrease in protein tyrosine phosphatase activities in vanadate-treated obese Zucker (fa/fa) rat liver
122. Enhanced in vivo sensitivity of vanadyl-treated diabetic rats to insulin
123. Insulin-stimulated glucose disposal in patients with type I (IDDM) and type II (NIDDM) diabetes mellitus
124. Non-insulin-like action of sodium orthovanadate in the isolated perfused liver of fed, non-diabetic rats
125. Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle
126. Glucose toxicity
127. Detection of oxovanadium (IV) and characterization of its ligand environment in subcellular fractions of the liver of rats treated with pentavalent vanadium(V)
128. Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats
129. Vanadium salts as insulin substitutes - Mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research
130. Vanadate elevates lipogenicity of starved rat adipose tissue-mechanism of action
131. Independent signal-transduction pathways for vanadate and for insulin in the activation of glycogen synthase and glycogenesis in rat adipocytes
132. Kinetic analysis and comparison of uptake, distribution, and excretion of 48V-labeled compounds in rats
133. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions
134. Effect of depletion of phosphate and bicarbonate ions on insulin action in rat adipocytes
135. Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes
136. A cytosolic protein tyrosine kinase in rat adipocytes
137. Mechanism of pervanadate stimulation and potentiation of insulin-activated glucose transport in rat adipocytes: Dissociation from vanadate effect
138. Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes
139. Vanadate: A potent inhibitor of multifunctional glucose-6-phosphatase
140. Vanadium ions stimulate DNA synthesis in Swiss mouse 3T3 and 3T6 cells
141. The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity nor phosphorylation in mouse diaphragm in vivo
142. Vanadate treatment of streptozotocin diabetic rats restores expression of the insulin-responsive glucose transporter in skeletal muscle
143. Role of IRS-2 in insulin and cytokine signalling
144. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate
145. A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes
146. Effects of vanadium on glucose metabolism in vitro
147. Vanadate down-regulates cell surface insulin and growth hormone receptors and inhibits insulin receptor degradation in cultured human lymphocytes
148. Vanadium compounds - Biological actions and potential as pharmacological agents
149. Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and Glut translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C
150. Inhibition of increasing effect of vanadate on glycogen content and lipoprotein lipase activity in fat pads by 5-N,N-hexamethylene amiloride
151. Vanadate treatment restores the expression of genes for key enzymes in the glucose and ketone bodies metabolism in the liver of diabetic rats
152. Vanadate potentiates the glycogenic action of insulin-like growth factors on isolated diaphragm
153. Antidiabetic action of vanadyl in rats independent of in vivo insulin-receptor kinase activity
154. Effects of vanadate on protein kinases in rat hepatocytes
155. Mechanisms of hyperglycemia-induced insulin resistance in whole body and skeletal muscle of type I diabetic patients
156. Distinct protein tyrosine phosphorylation during mitogenesis induced in quiescent SV40-transformed 3T3 T cells by insulin or vanadate
157. Activation of mesangial cells by the phosphatase inhibitor vanadate. Potential implications for diabetic nephropathy
158. Stimulatory (insulin-mimetic) and inhibitory (ouabain-like) action of vanadate on potassium uptake and cellular sodium and potassium in heart cells in culture
159. Disruption of IRS-2 causes type 2 diabetes in mice
160. Effects of peroxovanadate and vanadate on insulin binding, degradation and sensitivity in rat adipocytes
161. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration
162. Effects of low and high dose bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats
163. Acute and chronic oral administration of bis-(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats
164. Crystal structure of bovine low molecular weight phosphotyrosyl phosphatase complexed with the transition state analog vanadate